Design and evaluation of 32P-labeled hydroxyapatite nanoparticles for bone tumor therapy

Dongliang Zhai,Yumei Wang,Songke Yu,Jiren Zhou,Jia Song,Shilei Hao,Xiaoliang Chen
DOI: https://doi.org/10.1080/10717544.2023.2168791
IF: 6.819
2023-01-24
Drug Delivery
Abstract:The clinical diagnosis and treatment of malignant bone tumors are still major clinical challenges due to their high incidence are difficulty. Targeted therapies have become a critical approach to treat bone tumors. In recent years, radiopharmaceuticals have been used widely and have shown potent and efficient results in treating bone tumors, among which 32 P and the labeled radiopharmaceuticals play an essential role. In this study, the 32 P-labeled hydroxyapatite (HA) was prepared through chemical synthesis ( 32 P-Hap) and physical adsorption ( 32 P-doped-Hap). The in vitro stability of 32 P-labeled HA was analyzed to assess the superiority of the new-found chemical synthesis. The radiolabeling yield and stability of chemical synthesis (97.6 ± 0.5%) were significantly improved compared with physical adsorption (92.7 ± 0.4%). Furthermore, the CT results corroborate that 32 P-Hap (100 μCi) +DOX group has the highest tumor suppression rate and can effectively reduce bone destruction. The results corroborate the effectiveness of the chemical synthesis and validate the application of 32 P-Hap in bone tumors. Therefore, 32 P-Hap (100 μCi) + DOX may be an effective strategy for bone metastasis treatments.
pharmacology & pharmacy
What problem does this paper attempt to address?